Compare WRAP & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WRAP | BOLD |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.5M | 60.8M |
| IPO Year | 2017 | 2024 |
| Metric | WRAP | BOLD |
|---|---|---|
| Price | $1.38 | $2.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 465.0K | 116.6K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,672,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.66 | N/A |
| 52 Week Low | $1.04 | $0.96 |
| 52 Week High | $3.23 | $3.16 |
| Indicator | WRAP | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 34.76 | 34.56 |
| Support Level | $1.26 | $2.39 |
| Resistance Level | $1.37 | $2.64 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 3.85 | 4.57 |
Wrap Technologies Inc is a public safety technology and services company that delivers safe and effective policing solutions to law enforcement and security personnel. The firm develops policing solutions to law enforcement and security personnel. Its BolaWRAP 150 Remote Restraint device is a patented, hand-held tool that discharges a Kevlar cord to restrain noncompliant individuals from a range of 10-25 feet. The group operates in the Americas, Europe, the Middle East, Africa and the Asia Pacific.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.